跳到正文
原文
Regeneron· @Regeneron · X·· 2026-10-16精选AI 评分58
AI 导读

再生元宣布,欧洲药品管理局CHMP已推荐批准其免疫疗法在现有已获批的皮肤癌、肺癌和宫颈癌适应症中采用替代给药方案。该推荐覆盖上述三项适应症,公司未在帖文中披露具体给药间隔或药品名称。

推荐理由

CHMP对已获批皮肤、肺、宫颈癌适应症给出替代给药方案推荐,读者可据此了解该免疫疗法的用药便利性变化。

正文

We are pleased to share that the European Medicines Agency’s CHMP has recommended approval of an alternative dosing regimen for our immunotherapy across its currently approved skin, lung, and cervical cancer indications.

Learn more: https://bit.ly/4eDjCpJ

来源:Regeneron · x.com